Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
3(50%)
Results Posted
150%(3 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_1
1
17%
Ph phase_2
3
50%
Ph phase_3
2
33%

Phase Distribution

1

Early Stage

3

Mid Stage

2

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
3(50.0%)
Phase 3Large-scale testing
2(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

3

trials recruiting

Total Trials

6

all time

Status Distribution
Active(3)
Completed(2)
Terminated(1)

Detailed Status

Active, not recruiting3
Completed2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
3
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (16.7%)
Phase 23 (50.0%)
Phase 32 (33.3%)

Trials by Status

active_not_recruiting350%
completed233%
terminated117%

Recent Activity

3 active trials
Showing 5 of 6
active_not_recruitingphase_2

NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer

NCT06094140
active_not_recruitingphase_3

Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC

NCT01933932
active_not_recruitingphase_3

Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors

NCT02375204
completedphase_2

Minimal Islet Transplant at Diabetes Onset

NCT02505893
completedphase_1

Reversing Type 1 Diabetes After it is Established

NCT01106157
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT06094140Phase 2

NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer

Active Not Recruiting
NCT01933932Phase 3

Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC

Active Not Recruiting
NCT02375204Phase 3

Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors

Active Not Recruiting
NCT02505893Phase 2

Minimal Islet Transplant at Diabetes Onset

Completed
NCT01106157Phase 1

Reversing Type 1 Diabetes After it is Established

Completed
NCT02469116Phase 2

Carboplatin Plus Docetaxel With Day 2 Pegylated G-CSF (Neulasta®) in Patients With Advanced Stage Ovarian Carcinoma

Terminated

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6